It appears to be efficacious with similar doses to oral treatment, although it appears there may be more variability in compliance and thyroid concentrations 10
Nurses can provide education about lifestyle modifications, such as reducing caloric intake, increasing physical activity, and creating sustainable lifelong healthy habits to preventing rebound weight gain after discontinuing pharmacotherapy
In recent years, semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist administered as a once-weekly injection, has demonstrated significant efficacy in improving glycemic control, promoting weight loss, and alleviating hepatic steatosis (3)
Patients should contact their healthcare provider if they experience recurrent dizziness or lightheadedness that interferes with daily activities, particularly if symptoms persist beyond the first few weeks of therapy or occur with each dose increase
In a statement published on 11 June 2026, the MHRA said that the drug the first oral glucagon-like peptide-1 (GLP-1) available in the UK can be used in adults with obesity, who have a BMI of 30 or above, or who are overweight with a BMI between 27 and 30 and at least one weight-related comorbidity
For that, I apologize to Cardinals fans, my teammates, and the entire Cardinals organization
